Skip to main content

Phase 1 Rare Disease Deal Benchmarks

Median Upfront
$91M
Range: $35M - $152M
Total Deal Value
$846M
Range: $406M - $1.3B
Royalty Rate
5.6% - 11.2%
Tiered up to 15.2%
Dev Milestones
$264M
Range: $130M - $397M

Market Analysis

Phase 1 rare disease licensing deals carry a median total deal value of $846M, with upfront payments ranging from $35M to $152M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 11% to upfront and 89% to milestones.

The rare disease landscape at the phase 1 stage is characterized by limited competitive intensity per indication but growing platform competition. Development milestones average $264M, regulatory milestones contribute $204M, and commercial milestones reach $287M. Gene therapies and oligonucleotide-based approaches are transforming treatment paradigms, with orphan designations enabling premium pricing and accelerated regulatory paths.

Royalty rates for phase 1 rare disease deals range from 5.6% to 11.2% at the base tier, with high-tier escalation to 15.2%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 1 rare disease deals?
Phase 1 rare disease deals average $91M in upfront payments, ranging from $35M to $152M. The upfront allocation of 11% of total deal value reflects the clinical stage risk profile.
How are phase 1 rare disease deal milestones structured?
Milestones account for approximately 89% of total deal value. Development milestones ($264M) represent the largest component, followed by commercial milestones ($287M) and regulatory milestones ($204M).
What royalty rates are typical for phase 1 rare disease licensing?
Base royalty rates range from 5.6% to 11.2%, with tiered escalation to 9.6%-15.2% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included